©The Author(s) 2025.
World J Clin Oncol. Nov 24, 2025; 16(11): 111627
Published online Nov 24, 2025. doi: 10.5306/wjco.v16.i11.111627
Published online Nov 24, 2025. doi: 10.5306/wjco.v16.i11.111627
Figure 7 Correlation between ectonucleoside triphosphate diphosphohydrolase 6 expression and immunotherapy.
A: The association between ectonucleoside triphosphate diphosphohydrolase 6 expression and 51 immune checkpoint genes; B-D: Mismatch repair genes, microsatellite instability, as well as tumor mutational burden. aP < 0.05; bP < 0.01; cP < 0.001. ENTPD6: Ectonucleoside triphosphate diphosphohydrolase 6; MMR: Mismatch repair; MSI: Microsatellite instability; TMB: Tumor mutational burden.
- Citation: Wang G, Liu T, Zhang JX, Li YR, Zhu WJ, Wang JL, Dong WW, Zhang YY, Li YM, Yang LX, He LX, He WT. Systematic pan-cancer analysis reveals the prognostic and immunological roles of ectonucleoside triphosphate diphosphohydrolase 6. World J Clin Oncol 2025; 16(11): 111627
- URL: https://www.wjgnet.com/2218-4333/full/v16/i11/111627.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i11.111627